Methodological Considerations for Early-phase Development of Immune Checkpoint Inhibitors in Urothelial Bladder Cancer

Eur Urol. 2017 May;71(5):840-841. doi: 10.1016/j.eururo.2016.09.044. Epub 2016 Oct 6.

Authors

Andrea Necchi¹, Daniele Giardiello², Luigi Mariani²

Affiliations

¹ Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: [email protected].
² Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

PMID: 27720533
DOI: 10.1016/j.eururo.2016.09.044

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use*
B7-H1 Antigen / antagonists & inhibitors
B7-H1 Antigen / immunology
Data Interpretation, Statistical
Humans
Molecular Targeted Therapy
Probability
Research Design / statistics & numerical data*
Time Factors
Treatment Outcome
Urinary Bladder Neoplasms / drug therapy*
Urinary Bladder Neoplasms / immunology
Urinary Bladder Neoplasms / pathology
Urothelium / drug effects*
Urothelium / immunology
Urothelium / pathology

Substances

Antibodies, Monoclonal
Antineoplastic Agents, Immunological
B7-H1 Antigen
CD274 protein, human
durvalumab